To Explore the Correlation between Tumor and Immune Markers and HPV Expression and Prognosis in Patients with Cervical Cancer

Ezalia Bt. Isa, Xiangyang Zhu


The aim of this study was to investigate the correlation between immune cells and tumor markers and HPV levels in patients with cervical cancer with high-risk human papilloma virus (HPV) rate and their prognosis. Firstly, 83 cases of cervical intraepithelial neoplasia were selected as CINI group, 72 cases of cervical carcinoma as cervical cancer group and 50 cases of chronic cervicitis as chronic cervicitis group. The different expression levels of immune cells (CD4+, CD8+, Treg, CD4+/CD8+, CD56+,) and the positive expression of tumor markers (K-ras, Ki-67) inpatients with HPV were studied to explore the correlation between HPV levels and immune cells and tumor markers in cervical cancer patients with high-risk HPV infection, and that between positive expression of immune cells and tumor markers in patients with lymph node metastasis of cervical cancer with high-risk HPV infection, as well as that between the survival rate of patients and the immune cell levels and positive expression of tumor markers in patients who die of cervical cancer. The results showed that the levels of CD8 + and Treg in cervical cancer patients were higher than those in CIN group and chronic cervicitis group (P < 0.05). The levels of tumor markers were lower in those in CIN group and chronic cervicitis group (P < 0.05). The positive expression rates of K-ras and KI-67 in the three groups were significantly different (P < 0.05). In cervical cancer group, CD4 + and CD56+ were negatively correlated with HPV-DNA levels, and CD8 + and Treg levels as well as k-RAS and KI-67 positive expression were positively correlated with HPV-DNA levels. The levels of immune markers in cervical cancer group were significantly lower than those in surviving patients (P < 0.01), while the levels of CD8 + and Treg, the proportion of K-RA and KI-67 were significantly higher than those in surviving patients (P < 0.01). Therefore, for patients with CIN, chronic cervicitis patients with high-risk HPV infection, and cervical cancer patients with reduced immune function and high-risk HPV infection, the expression of tumor markers K-ras and Ki-67 was increased. The detection of immune cells and tumor markers is helpful for the early prevention, diagnosis and prognosis evaluation of high-risk HPV infection in patients with cervical cancer.


HPV diagnosis; Prognosis; Immune cells; Tumor markers

Full Text:



Wang Hairui, Liao Guangdong, Jiang Yu, etc. The diagnostic value of. P16/mcm2 dual staining in cervical intraepithelial neoplasia and its relationship with high-risk HPV infection [J].China Journal of Epidemiology, 2017, 38 (9): 1241-1245.

Zhou Wu, Chen Zhanguo, Tao Zhihua, etc. Relationship between multiple infections and age factors of different HPV subtypes and cervical lesions [J]. Chinese Journal of Health Laboratory Technology, 2008, 18 (12): 2632-2634.

Zhang Jianying, Liu Ban, Zhang Yimin, etc. Changes of regulatory T cells in peripheral blood of patients with cervical cancer and their clinical significance [J]. Chinese Journal of Microbiology and Immunology, 2015, 35 (10): 753-758.

Philippe A, Rassy M, Craciun L, et al. Inflammatory stroma of lymphoepithelioma-like carcinoma of the cervix: immu- nohistochemical study of 3 cases and review of the literature [J]. Int J Gynecol Pathol, 2018, 37(5): 482-487.

Zhou Qi, Long Ling, Zeng Li. Analysis of HPV infection and expression of CD4 + and CD8 + in cervical carcinoma [J]. Journal of Pathogen Biology, 2016, 11 (9): 851-854.

Ma Chao, Li Peiyu, Zhang Nan, etc. The expression of. α-SMA and Ki-67 in patients with primary retroperitoneal leiomyosarcoma [J]. Chinese Journal of Oncology, 2018, 40 (4): 258-263.

Liu Haiqing, Lv Jieqiang. High-risk human papillomavirus and k-ras, c-myc gene expression in cervical exfoliated cells and their correlation with cervical intraepithelial neoplasia [J].Chinese Journal of Practical Gynecology and Obstetrics, 2015, 31 (12): 1121-1124.

Lin Zhongqiu, Wu Juna. FIGO 2009 New staging of vulva carcinoma, cervical carcinoma and endometrial carcinoma [J]. Journal of International Obstetrics and Gynecology, 2009, 36 (5): 411-412.

Feng Youji, Li Helian. Obstetrics [M]. Beijing: People's Health Press, 2002: 233-235; 270-271. Gynecol Oncol, 20 17, 144 (1): 51-56.

Ewaisha R, Panicker G, Maranian P, et al. Serum immune profiling for early detection of cervical disease [J]. Ther- anostics, 2017, 7(16): 3814-3823.

Zhang T, Jiao J, Jiao X, et al. Aberrant frequency of TN- FR2+ Treg and related cytokines in patients with CIN and cervical cancer[J]. Oncotarget, 2017, 9(4): 5073-5083.

Wright TC, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytolo- gy: results from a sub-study nested into the ATHENA trial

Veluchamy JP, Heeren AM, Spanholtz J, et al. High-effi- ciency lysis of cervical cancer by allogeneic NK cells de- rived from umbilical cord progenitors is independent of HLA status[J]. Cancer Immunol Immunother, 2017, 66(1): 51-61.

van Poelgeest MI, Visconti VV, Aghai Z, et al. Potential use of lymph node-derived HPV-specific T cells for adop- tive cell therapy of cervical cancer[J]. Cancer Immunol Immunother, 2016, 65(12): 1451-1463.

Cavard C, Audebourg A, Letourneur F, et al. Gene expres- sion profiling provides insights into the pathways in- volved in solid pseudopapillary neoplasm of the pancreas [J]. J Pathol, 2009, 218(2): 201-209.

Wright TC, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytolo- gy: results from a sub-study nested into the ATHENA trial

Cancer Immunol Immunother, 20 17, 66 (1): 51-61.

Zhan Hanxiang, Cheng Yugang, Han Haifeng, etc. The clinical features and treatment of pancreatic solid pseudopapilloma [J].Chinese Journal of Digestive Surgery, 2017, 16 (10): 1005-1012.

Song He, Dong Ming, Zhou Jianping, etc. Clinical diagnosis and treatment of pancreatic solid pseudopapiloma [J]. Chinese Journal of General Surgery, 2016, 31 (1): 1-3.

Guimarães LS, de Melo AM, Ruiz MR, et al. Solid pseudo- papillary tumor of the pancreatic: evaluation of clinical, ra- diological and surgical profiles [J]. Rev Col Bras Cir, 2013, 40(5): 398-403.

Murhekar K, Ramakrishnan AS, Ramani B, et al. Solid pseudo-papillary tumor of pancreas: A rare case report and review of Indian literature [J]. J Cancer Res Ther, 2013, 9 (3): 507-510.[20]

Buetow PC, Buck JL, Pantongrag-Brown L, et al. Solid and papillary epithelial neoplasm of the pancreas: imaging- pathologic correlation on 56 cases [J]. J Radiology, 1996, 199: 707-711.

Zhang Kai, Ma Chao, Ding Yuechao, etc. Operative experience in 69 patients with solid papilloma of pancreas [J]. Chinese Journal of Modern Medicine, 2017, 27 (5): 135-137.

Guermehe Y, Soyer P, Dohan A, et al. Solid-pseudopapil- lary tumor of the pancreas: MR imaging findings in 21 pa- tients[J]. Clin Imaging, 2014, 38(4): 475-482.

Sui Yanxia, Dang Chengxue, Zhang Yong, etc. Primary pancreatic neuroendocrine tumor: A clinicopathological analysis of 60 cases. Chinese Journal of Clinical and Experimental Pathology, 2015, 31 (8): 873-876.

Yang Yang, Zhang Xv, Li Bing. Diagnosis and treatment of 32 cases of pancreatic mucinous cystic tumors [J]. Journal of Dalian Medical University, 2017, 39 (1): 62-65.

Kosmahl M, Seada LS, Jänig U, et al. Solid-pseudopapil-lary tumor of the pancreas: its origin revisited[J]. Vir- chows Arch, 2000, 436(5): 473-480.

Zhang H, Liang TB, Wang WL, et al. Diagnosis and treat- ment of solid- pseudopapillary tumor of the pancreas[J]. Hepatobiliary Pancreat Dis Int, 2006, 5(3): 454-458.

Miao J, Kusafuka T, Kuroda S, et al. Mutation of beta- catenin and its protein accumulation in solid and cystic tu- mor of the pancreas associated with metastasi[J]. Int J Mol Med, 2003, 11(4): 461-464.

Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseu- dopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations[J]. Am J Pathol, 2002, 60(4): 1361-1369.



  • There are currently no refbacks.

Copyright (c) 2020 Ezalia Bt. Isa, Xiangyang Zhu

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.